CorVel Corp. 10-Q Summary: Quarter Ended June 30, 2010
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended June 30, 2010 for CorVel Corporation, a nationwide provider of medical cost containment and managed care services. The company serves insurance companies, third-party administrators (TPAs), and self-administered employers, primarily in the workers' compensation and auto insurance sectors. Services are categorized into Network Solutions (e.g., medical fee auditing, PPO management) and Patient Management (e.g., case management, utilization review).
Key Financial Metrics
| Metric | Q2 2010 | Q2 2009 |
|---|---|---|
| Revenues | $91.5 million | $81.3 million |
| Cost of Revenues | $67.7 million | $60.2 million |
| Gross Profit | $23.8 million | $21.1 million |
| Gross Margin | 26.0% | 26.0% |
| Net Income | $7.8 million | $6.4 million |
| Diluted EPS | $0.64 | $0.49 |
| Cash from Operations | $11.5 million | $7.8 million |
| Cash and Equivalents (End of Period) | $13.7 million | $20.2 million |
| Debt | $0 (No outstanding revolving loans) | $0 |
Material Changes vs. Prior Period
- Revenue Growth: Revenues increased 12.5% year-over-year. This was driven primarily by a 26.6% increase in Patient Management services (due to higher TPA utilization) and a 2.3% increase in Network Solutions (driven by directed care services).
- Profitability: Net income rose 21.2% to $7.8 million. Diluted earnings per share increased 30.6% to $0.64, aided by both higher income and a reduction in the share count due to buybacks.
- Expenses: Cost of revenues increased 12.5%, mirroring revenue growth due to higher costs in TPA, pharmacy, and directed care services. General and administrative expenses rose 9.9%, largely due to increased systems development and legal costs.
- Share Count: Weighted average diluted shares decreased 6.7% to 12.2 million, reflecting aggressive share repurchases.
Outlook, Risks, and Management Commentary
- Capital Allocation: The company continues its share repurchase program. In Q2 2010, it repurchased 153,287 shares for $5.5 million. The Board expanded the program authorization to 15 million shares total in June 2010.
- Liquidity: The company maintains a $10 million revolving credit facility with no outstanding borrowings. Letters of credit totaling $6.3 million are issued against this facility. Management believes cash from operations is sufficient for the next 12 months.
- Legal Contingencies: A significant putative class action lawsuit (Roche v. CorVel) remains pending regarding alleged failures to direct patients to PPO network providers and the use of biased software. The company cannot estimate potential losses but intends to defend vigorously.
- Regulatory Risks: The company faces risks from changing government regulations in workers' compensation and healthcare, which could increase operational costs or reduce demand for services.
- Accounting Updates: The company is reviewing the impact of FASB ASU 2009-13 regarding multiple deliverable revenue arrangements, effective April 1, 2011.
Investor Verification Checklist
- Verify the status and potential financial impact of the Roche class action litigation, as the company states it cannot estimate the loss.
- Monitor the sustainability of the 26.6% growth in Patient Management services, which drove the majority of revenue increases.
- Review the share repurchase program progress and remaining authorization (1.07 million shares remaining as of June 30, 2010).
- Assess the impact of rising legal and systems costs on future operating margins.
- Confirm the company's ability to maintain its credit facility covenants (current ratio of 1.25:1 and positive net income) as it continues to invest in software development.